Subsidiary Governance Risk: The Hidden Accountability Gap Inside UK Group Companies

Why It Matters

The shift forces boards to align operational control with statutory accountability, turning informal oversight into a tangible compliance liability that can directly impact a company’s ability to operate and raise capital.

Key Takeaways

• UK groups face operational subsidiary governance risk under new reforms
• 2023 Economic Crime Act empowers Companies House to reject filings
• Informal parent control creates audit‑trail gaps, exposing subsidiary boards
• Boards must formalise group influence with documented approvals and evidence standards
• Testing governance during appointments and filings mitigates regulatory scrutiny

Pulse Analysis

The UK’s tightening corporate transparency regime is reshaping how conglomerates manage their subsidiaries. While the Companies Act 2006 still places fiduciary duties on subsidiary directors, the Economic Crime and Corporate Transparency Act 2023 has turned Companies House into an active gatekeeper. This means routine filings—director appointments, statutory returns, and shareholder disclosures—can be stalled or rejected if the underlying governance cannot be substantiated. The practical effect is a shift from a paper‑based compliance checklist to a real‑time audit of decision pathways, forcing groups to embed formal approval mechanisms at every legal entity.

At the heart of the issue is the disconnect between de‑facto control exercised by parent boards and the de‑jure responsibilities of subsidiary directors. Informal directives may speed operations, but they erode the audit trail required under the new regime. Boards that rely on unwritten group guidance risk exposing themselves to liability when regulators demand proof of who authorised a decision and under what authority. To close this gap, companies are adopting documented shareholder resolutions, formal board minutes, and clear delegation registers that map group strategy to subsidiary execution, thereby creating a defensible evidence base.

Looking ahead, the emphasis will move from the design of governance frameworks to their demonstrable effectiveness. Companies that embed disciplined, evidence‑first processes—such as regular governance health checks during key events like appointments or filing cycles—will not only meet regulatory expectations but also strengthen stakeholder confidence. Conversely, firms that continue to depend on informal control structures may find their governance appearing robust on paper while failing under scrutiny, potentially jeopardising access to capital and market reputation.